We are live on ! Find out more
BLTE

Belite Bio
BLTE

6 hedge funds and large institutions have $14.9M invested in Belite Bio in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.4% more ownership

Funds ownership: 3.42% → 3.82% (+0.4%)

25% less funds holding

Funds holding: 8 → 6 (-2)

41% less capital invested

Capital invested by funds: $25.4M → $14.9M (-$10.5M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
6
Holders Change
-2
Holders Change %
-25%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$4.79M
2
AWS
Atria Wealth Solutions
New York
+$54.5K
3
State Street
State Street
Massachusetts
+$20.9K
4
UBS Group
UBS Group
Switzerland
+$4.09K

Top Sellers

Rank Fund Capital Flow
1
AA
ALPS Advisors
Colorado
-$458K
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$219K
3
Morgan Stanley
Morgan Stanley
New York
-$13.6K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$3K
5
BlackRock
BlackRock
New York
-$2.07K

BLTE Hedge Fund Activity: Q2 2023 in Review

6 of the 6,384 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q2 2023, worth a combined $14.9M — down 41% from $25.4M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BLTE and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $4.79M. The largest seller was ALPS Advisors, exiting entirely with an estimated $458K sold.

  • 6 institutional investors held Belite Bio (BLTE) as of Q2 2023, down from 8 in Q1 2023.
  • Funds reported $14.9M of Belite Bio stock for Q2 2023, down 41% quarter-over-quarter.
  • 1 fund opened new Belite Bio positions in Q2 2023 and 3 closed out, a net change of -2 holders.
  • The largest Belite Bio buyer in Q2 2023 was Armistice Capital, an estimated $4.79M added.
  • The largest Belite Bio seller in Q2 2023 was ALPS Advisors, an estimated $458K sold.

Based on aggregated 13F filings for Q2 2023.